Development of a novel connexin-based peptide for the treatment of corneal injury

开发用于治疗角膜损伤的新型连接蛋白肽

基本信息

  • 批准号:
    8198936
  • 负责人:
  • 金额:
    $ 23.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-03-01 至 2013-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): According to the World Health Organization, at least 171 million people worldwide are living with diabetes and this figure is likely to more than double by the year 2030. Because of its chronic nature, the severity of its complications and the means required to control them, the economic burden is enormous not only to the individuals and families involved but also to the health system. Wound healing in diabetics, in general, is severely impaired, which has a great impact on the economic and social burden of our society. Diabetes is the leading cause of new cases of blindness among adults aged 20-74 years. Although retinopathy is the primary cause of blindness in these patients, in the past 3 decades it has been noted that 47-64% of diabetic patients will manifest diabetic keratopathy or other corneal abnormalities, which are potentially sight threatening. Currently, therapies to treat these corneal epithelial wounds are very limited. FirstString Research, Inc is an early stage biotech company developing therapeutic peptides for applications in tissue engineering and regenerative medicine. FirstString's lead novel bioengineered peptide dubbed ACT1, is based on the C-terminal sequence of connexin 43 (Cx43), and shows great promise in modulating intercellular communication. ACT1 works by stabilizing gap junctions and maintaining intercellular communication between cells that is essential for wound repair or injury response. Preliminary data from our company has indicated that this peptide can effect accelerated wound healing, reduce inflammatory response, reduce scar formation and restore skin structure following acute injury in a diabetic mouse model system. Furthermore, ACT1 peptide has been shown to promote corneal wound closure following ethanol burn injuries to the rat cornea, compared with that of a control peptide. Based on these early findings we hypothesize that ACT1 peptide will increase corneal re-epithelialization and accelerate wound closure following injury to the corneas of diabetic rats as demonstrated by the aims outlined in this Phase I SBIR application. The completion of aims outlined in this project will set the stage for a future Phase II SBIR and could lead to a commercially viable therapeutic in the clinical management of diabetic keratopathy. PUBLIC HEALTH RELEVANCE: According to the World Health Organization, at least 171 million people worldwide are living with diabetes. Corneal disorders secondary to diabetes, such as diabetic keratopathy, are an increasing cause of morbidity associated with diabetes and affects 47-64% of diabetics during the course of their disease. Conventional therapies for the treatment of these corneal wounds have failed. FirstString Research Inc. has developed a novel therapeutic peptide that may promote re-epithelialization of the cornea, reduce scarring and inflammation and thereby prevent potential blindness in diabetics with such disorders.
描述(由申请人提供):根据世界卫生组织,全球至少有1.71亿人患有糖尿病,到2030年,这一数字可能会增加一倍以上。由于其慢性性质、并发症的严重性以及控制这些并发症所需的手段,不仅对所涉个人和家庭,而且对卫生系统来说,经济负担都是巨大的。糖尿病患者的伤口愈合通常严重受损,这对我们社会的经济和社会负担具有很大影响。糖尿病是20-74岁成年人新失明病例的主要原因。虽然视网膜病变是这些患者失明的主要原因,但在过去的30年中,已经注意到47-64%的糖尿病患者会表现出糖尿病性角膜病变或其他角膜异常,这可能威胁视力。目前,治疗这些角膜上皮伤口的疗法非常有限。FirstString Research,Inc是一家早期生物技术公司,开发用于组织工程和再生医学的治疗肽。FirstString的领先的新型生物工程肽被称为ACT 1,基于连接蛋白43(Cx43)的C末端序列,在调节细胞间通讯方面显示出巨大的前景。ACT 1通过稳定间隙连接和维持细胞间的通讯发挥作用,这对伤口修复或损伤反应至关重要。我们公司的初步数据表明,这种肽可以加速伤口愈合,减少炎症反应,减少瘢痕形成,并在糖尿病小鼠模型系统中恢复急性损伤后的皮肤结构。此外,与对照肽相比,ACT 1肽已显示出促进大鼠角膜乙醇烧伤后的角膜伤口闭合。基于这些早期发现,我们假设ACT 1肽将增加糖尿病大鼠角膜损伤后的角膜上皮再生并加速伤口闭合,如本I期SBIR申请中概述的目的所证明的。该项目中概述的目标的完成将为未来的II期SBIR奠定基础,并可能导致糖尿病角膜病变临床管理中的商业可行治疗。 公共卫生相关性:根据世界卫生组织的数据,全球至少有1.71亿人患有糖尿病。继发于糖尿病的角膜疾病,例如糖尿病性角膜病变,是糖尿病相关发病率的增加原因,并且在糖尿病患者的病程期间影响47-64%的糖尿病患者。用于治疗这些角膜伤口的常规疗法已经失败。FirstString Research Inc.已经开发了一种新的治疗肽,其可以促进角膜的上皮再生,减少瘢痕形成和炎症,从而防止患有这种疾病的糖尿病患者的潜在失明。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gautam Sudhir Ghatnekar其他文献

Gautam Sudhir Ghatnekar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gautam Sudhir Ghatnekar', 18)}}的其他基金

Improving marginal allograft outcomes through cell junction stabilization in transplantation
通过移植中的细胞连接稳定性改善边缘同种异体移植结果
  • 批准号:
    10018537
  • 财政年份:
    2020
  • 资助金额:
    $ 23.28万
  • 项目类别:
Novel small molecule HSP90 inhibitor for the management of atopic dermatitis
用于治疗特应性皮炎的新型小分子 HSP90 抑制剂
  • 批准号:
    10016726
  • 财政年份:
    2020
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation of a Connexin-based Peptide for the Treatment of Age-Related Macular Degeneration
基于连接蛋白的肽治疗年龄相关性黄斑变性的评价
  • 批准号:
    9346869
  • 财政年份:
    2017
  • 资助金额:
    $ 23.28万
  • 项目类别:
Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury
间隙/紧密连接的稳定以改善脑死亡引起的内皮细胞损伤
  • 批准号:
    9141772
  • 财政年份:
    2016
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation of a novel connexin-based peptide for the treatment of diabetic wounds
一种新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    7405169
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    9100741
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds
新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    9202629
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    8046461
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    8285078
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
新型连接蛋白肽治疗糖尿病伤口的评价
  • 批准号:
    7801887
  • 财政年份:
    2007
  • 资助金额:
    $ 23.28万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 23.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了